1020717-99-0 Usage
General Description
4-Bromo-5-fluoro-2-nitrobenzoic acid is a chemical compound with the molecular formula C7H3BrFNO4. It is a nitrobenzoic acid derivative that has a bromine atom at the 4th position, a fluorine atom at the 5th position, and a nitro group at the 2nd position on the benzene ring. 4-Bromo-5-fluoro-2-nitrobenzoic acid is commonly used as a building block in organic synthesis and pharmaceutical research. It is known for its ability to undergo various chemical reactions, making it a valuable intermediate in the production of pharmaceuticals, agrochemicals, and dyes. Its unique structural properties and reactivity make it a versatile compound for use in a wide range of applications in the field of chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1020717-99-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,0,7,1 and 7 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1020717-99:
(9*1)+(8*0)+(7*2)+(6*0)+(5*7)+(4*1)+(3*7)+(2*9)+(1*9)=110
110 % 10 = 0
So 1020717-99-0 is a valid CAS Registry Number.
1020717-99-0Relevant articles and documents
ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF
-
Page/Page column 62; 75, (2021/01/22)
The disclosure relates to compounds that act as an allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.
Burton's tyrosine kinase inhibitor
-
Paragraph 0124; 0125; 0126, (2017/01/17)
The invention provides a Burton's tyrosine kinase inhibitor. Particularly, a compound capable of serving as the Btk inhibitor is obtained through a wide and thorough research. It is shown through experimental results that the compound has a good inhibitin
TRICYCLIC SULFONAMIDE DERIVATIVES
-
Paragraph 1175-177, (2015/07/15)
The invention relates to derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of pain.
